THE US Food and Drug
Administration has approved
Picato(R) (ingenol mebutate) gel
(0.015%, 0.05%) as a treatment for
actinic keratoses (AK) on the face,
scalp, trunk and extremities.
The gel is designed to be used as
a once daily field-directed topical
treatment for AK, a potential
precursor to non-melanoma skin
cancer caused by cumulative sun
exposure.
Treatment with Picato(R) gel is
completed over two consecutive
days for AK on the trunk and
extremities and over three
consecutive days on the face and
scalp.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jan 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jan 12
THE Pharmacy Guild of Australia, Queensland, has elected Jess Burrey (pictured left) as a new member of its branch committee, following the completion of its stage one elections.
LTR Pharma, an ASX-listed company focused on men’s health, has won the prestigious IPO of the Year Award, underscoring its entry into the public market.
A NEW study published in the BMJ has revealed that people with type 1 diabetes are living longer, though significant global inequalities remain in diabetes care.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.